Stocks TelegraphStocks Telegraph
Stock Ideas

ST Premium

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!

PIRS Financial Statements and Analysis

NASDAQ : PIRS

Pieris Pharmaceuticals, Inc.

$13.60
-2.51-15.58%
Open: 4:00 PM
Not Actively Trading
70.41
BESG ScoreESG Rating

PIRS FINANCIAL STATEMENTS

An instrumental part of fundamental analysis is measuring key indicators of an asset, which are the factors that can influence its value and price. However, sometimes investors show more interest in financial statements with other factors to determine whether investing in that company is the right decision. Financial statements of a company include:

  • Balance Sheet
  • Income Statement
  • Cash Flow Statement

PIRS Income Statement

A company's income statement helps investors and business owners determine whether the company is profitable or losing money. Profitability is a key factor investors consider before investing in a stock. Income statements provide them with information about a company's profitability over time. The statement also enables them to observe trends in company spending and earnings since it breaks down individual costs and revenues. Income statements also provide details on where a company's money is going when it isn't profitable or its profits fluctuate.

Date2024-09-302024-06-302024-03-312023-12-312023-09-30
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202420232023
periodQ3Q2Q1Q4Q3
revenue0053.00K1.299M19.52M
cost of revenue0751.00K-30.00K4.454M739.00K
gross profit0-751.00K83.00K-3.155M18.781M
gross profit ratio001.566-2.4290.962
research and development expenses-446.00K751.00K1.248M4.454M9.595M
general and administrative expenses3.581M3.426M4.138M2.327M6.839M
selling and marketing expenses00000
selling general and administrative expenses3.581M3.426M4.138M2.327M6.839M
other expenses00171.00K0506.00K
operating expenses3.135M4.177M5.386M6.781M16.434M
cost and expenses3.135M4.177M5.356M6.781M16.434M
interest income169.00K201.00K240.00K455.00K549.00K
interest expense00000
depreciation and amortization0-1.00-30.00K476.00K708.00K
ebitda-3.135M-4.177M-5.303M-5.705M18.687M
ebitda ratio00-100.623-4.3920.957
operating income-3.135M-4.177M-5.303M-5.482M-11.807M
operating income ratio00-100.057-4.22-0.605
total other income expenses net248.00K586.999K411.00K898.00K-14.387M
income before tax-2.887M-3.59M-4.892M-4.584M-10.752M
income before tax ratio00-92.302-3.529-0.551
income tax expense00-73.276K-699.00K14.344M
net income-2.887M-3.59M-4.892M-4.584M-10.752M
net income ratio00-92.302-3.529-0.551
eps-2.19-2.76-3.95-3.71-0.11
eps diluted-2.19-2.76-3.95-3.71-0.11
weighted average shs out1.32M1.299M1.237M1.237M98.852M
weighted average shs out dil1.32M1.299M1.237M1.237M98.852M
Graph

PIRS Balance Sheet

Balance sheet summarizes a company's financials and can be used as a basis by investors to determine the value of a company. It shows the value of the stock, as well as the assets and liabilities of the company. A company's balance sheet displays how its assets are put to use and how those assets are financed, based on the liabilities section. Both investors and analysts analyze a company's balance sheet to determine how it allocates its resources.

Date2024-09-302024-06-302024-03-312023-12-312023-09-30
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202420232023
periodQ3Q2Q1Q4Q3
cash and cash equivalents19.363M19.731M19.084M17.396M32.894M
short term investments0008.97M11.916M
cash and short term investments19.363M19.731M19.084M26.366M44.81M
net receivables879.00K4.671M7.245M6.039M3.029M
inventory00002.098M
other current assets280.00K649.00K3.168M6.275M9.152M
total current assets20.522M25.051M29.497M38.68M59.089M
property plant equipment net00196.00K01.984M
goodwill00000
intangible assets00000
goodwill and intangible assets00000
long term investments00000
tax assets00000
other non current assets0000-1.697M
total non current assets00196.00K0287.00K
other assets00-196.00K00
total assets20.522M25.051M29.497M38.68M59.376M
account payables801.00K969.00K1.518M3.372M4.164M
short term debt000012.292M
tax payables00000
deferred revenue0000994.00K
other current liabilities3.453M5.377M6.015M8.55M11.416M
total current liabilities4.254M6.346M7.533M11.922M28.866M
long term debt00000
deferred revenue non current00000
deferred tax liabilities non current00000
other non current liabilities00000
total non current liabilities00000
other liabilities00000
capital lease obligations000012.292M
total liabilities4.254M6.346M7.533M11.922M28.866M
preferred stock00000
common stock1.00K1.00K1.00K98.00K99.00K
retained earnings-326.333M-323.446M-319.856M-314.964M-310.38M
accumulated other comprehensive income loss-316.00K-436.00K-346.00K28.00K-339.00K
other total stockholders equity342.916M342.586M342.165M341.596M341.13M
total stockholders equity16.268M18.705M21.964M26.758M30.51M
total equity16.268M18.705M21.964M26.758M30.51M
total liabilities and stockholders equity20.522M25.051M29.497M38.68M59.376M
minority interest00000
total investments0008.97M11.916M
total debt000012.292M
net debt-19.363M-19.731M-19.084M-17.396M-20.602M
Graph

PIRS Cash Flow

A cash flow statement is regarded as a valuable indicator of profitability and the long-term outlook for a company. It assists the company in evaluating whether it has sufficient funds to cover its expenses. Essentially, a cash flow statement represents an organization's financial health. The cash flow statement, which measures the business's ability to operate in the short as well as long term, is broken down into operating, investing, and financing activities.

Date2024-06-302024-03-312023-12-312023-09-302023-06-30
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202320232023
periodQ2Q1Q4Q3Q2
deferred income tax00014.893M-106.00K
stock based compensation421.00K472.00K0966.00K1.048M
change in working capital2.192M-3.963M-14.337M-15.519M-18.892M
accounts receivables00000
inventory00000
accounts payables00000
other working capital2.748M-3.407M000
other non cash items-82.00K1.829M-748.00K-19.00K-182.00K
net cash provided by operating activities-1.48M-6.996M-19.669M-9.723M-13.431M
investments in property plant and equipment0013.00K-69.00K-67.00K
acquisitions net00001.299M
purchases of investments00-7.565M-7.027M-6.699M
sales maturities of investments2.176M9.00M11.001M5.112M5.40M
other investing activites2.176M9.00M00-1.299M
net cash used for investing activites2.176M9.00M3.449M-1.984M-1.366M
debt repayment00000
common stock issued0014.00K019.729M
common stock repurchased00000
dividends paid00000
other financing activites000052.00K
net cash used provided by financing activities0014.00K019.781M
effect of forex changes on cash-49.00K-316.00K708.00K-337.00K212.00K
net change in cash647.00K1.688M-15.498M-12.044M5.196M
cash at end of period19.731M19.084M17.396M32.894M44.938M
cash at beginning of period19.084M17.396M32.894M44.938M39.742M
operating cashflow-1.48M-6.996M-19.669M-9.723M-13.431M
capital expenditure0013.00K-69.00K-67.00K
free cash flow-1.48M-6.996M-19.656M-9.792M-13.498M
Graph

Frequently Asked Questions

How did Pieris Pharmaceuticals, Inc. do last quarter? What was its Total Revenue and Cost of Revenue?
A company's Total Revenue reveals how much money it generates before any expenses or deductions are made. As a result, this metric informs investors/stakeholders how much money the business makes. Tracking and understanding it is essential for evaluating a company's growth. As opposed to revenue, Cost of Revenue is any expenses a business incur to generate revenue. There can be high revenue in a business, but if the costs are high, it won't make a profit and will go out of business when money runs out. Therefore, PIRS generated $0.00 in revenue last quarter, while its costs came in at $0.00.
Last quarter, how much Gross Profit did Pieris Pharmaceuticals, Inc. report?
A business's Gross Profit is a key indicator of its profitability and financial performance. In other words, it reflects how efficiently a business uses labor, raw materials, and other resources. Pieris Pharmaceuticals, Inc. reported a $0.00 Gross Profit for the quarter ended Jun 30, 2024.
Have PIRS's Total Operating Expenses and Operating Income been favorable recently?
Operational Expenses represent the costs a company must incur to generate revenue, which is the ultimate goal of a business, whereas Operating Income shows the revenue left after operational direct and indirect costs have been deducted. PIRS incurred $3.14M worth of Operating Expenses, while it generated -$3.14M worth of Operating Income.
How much Net Income has PIRS posted recently?
The Net Income of a company is one of the factors investors consider when investing in the company. According to recent earnings report from Pieris Pharmaceuticals, Inc., the company generated -$2.89M in Net Income. When a company has a history of consistent net income, investors are more likely to invest in it since they know they will get a return.
At the end of the last quarter, how much Cash and Equivalents did Pieris Pharmaceuticals, Inc. have?
The amount of Cash and Cash Equivalents is an effective indicator of the financial strength and well-being of a company. An excess cash situation occurs when a company has more cash and cash equivalents than it needs for operating activities. The amount of Cash and Cash Equivalents available to Pieris Pharmaceuticals, Inc. as of the end of the last quarter was $19.36M.
What are PIRS's Total Net Receivables for the last quarter?
Total Net Receivables are a company's outstanding debts to its customers. Therefore, it refers to the amount that a company expects to collect from its customers. The higher a company's net receivables are, the more confident it is that it can collect money from its debtors. As of the end of the last quarter, PIRS had Total Net Receivables of $879.00K.
In terms of Total Assets and Current Assets, where did Pieris Pharmaceuticals, Inc. stand at?
An asset with an economic value within a year is considered a current asset. Total assets, however, also include long-term fixed assets, intangible assets, and other non-current assets. The current Assets of PIRS were $20.52M, while the Total Assets stand at $20.52M.
As of the last quarter, how much Total Debt did Pieris Pharmaceuticals, Inc. have?
The total debt of a business refers to how much it borrows. A company's current and long-term liabilities are added together to calculate its Total Debt. A debt ratio may be taken into account on a balance sheet by financial lenders, investors, and business leaders when making informed decisions about future loans or investments. The total amount of PIRS's debt was $0.00 at the end of the last quarter.
What were PIRS's Total Liabilities during the last reported quarter?
A company's total liabilities are the sum of all debts it is liable for, including any off-balance shee liabilities it may incur. This can be calculated by adding up all short-term and long-term liabilities. In its last quarter, PIRS reported total liabilities of $4.25M.
How much did PIRS's Working Capital change over the last quarter?
Working Capital Change for PIRS was $2.19M over the last quarter. Working Capital Change refers to the difference between net working capital amounts at the end of one accounting period and the end of another. It tells investors/stakeholders how much the company's cash flow will differ from its Net Income (i.e., after-tax profits). More powerful companies often have positive Change in Working Capital numbers as they have increased control over collecting cash from customers and delaying payments to suppliers.
PIRS generated how much cash from operating activities?
An operating cash flow statement usually contains cash from operating activities in the first section. An organization's cash from operating activities refers to the money it takes in and takes out as a result of its regular business operations. PIRS generated -$1.48M of Cash from Operating Activities during its recently reported quarter.
What was PIRS's latest reported Net Change in Cash?
An increase or decrease in cash and cash equivalent balances within a specified period is considered the net change in cash in a cash flow statement. Furthermore, it takes into account cash changes as a result of investments, financing, and operating activities. PIRS reported a $647.00K Net Change in Cash in the most recent quarter.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph